Parataxis Korea, Inc. (KOSDAQ:288330)

Market Cap	80.72B -59.7%
Revenue (ttm)	10.10M +834.3%
Net Income	-17.01B
EPS	-286.77
Shares Out	106.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	765,145
Average Volume	791,718
Open	776.00
Previous Close	n/a
Day's Range	740.00 - 796.00
52-Week Range	671.00 - 9,280.00
Beta	2.01
RSI	34.64
Earnings Date	Mar 20, 2026

About Parataxis Korea

Parataxis Korea, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration with Atomw...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 21
• Stock Exchange: KOSDAQ
• Ticker Symbol: 288330

Financial Performance

In 2024, Parataxis Korea's revenue was 2.18 million, a decrease of -97.82% compared to the previous year's 100.00 million. Losses were -19.76 billion, -53.32% less than in 2023.